Research analysts at FBR & Co initiated coverage on shares of Syndax Pharmaceuticals Inc (NDAQ:SNDX) in a report released on Thursday. The brokerage set an “outperform” rating and a $27.00 price target on the stock.

Separately, Instinet started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, March 2nd. They set a “buy” rating and a $27.00 price objective for the company.

Shares of Syndax Pharmaceuticals (NDAQ:SNDX) opened at 14.71 on Thursday. The firm’s market capitalization is $268.06 million. Syndax Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $18.03. The firm’s 50-day moving average price is $11.01 and its 200 day moving average price is $11.03.

Your IP Address:

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.